CLSA analysts downgraded Dr. Reddy's Laboratories shares, trading on both BSE (DRRD:IN) and NYSE (NYSE:RDY), from a Hold to an Underperform rating, adjusting the price target from INR1,140 to INR1,090 ...

Despite weak Q3 earnings, Bharat Petroleum (BPCL) draws attention from global brokerages. CLSA upgraded BPCL to ‘Hold’ with a ...

Shares of UltraTech Cement Ltd. fell on Friday despite the third quarter numbers being slightly ahead of expectations.

The firm expects mid-single-digit price erosion in generic drugs and heightened competition for key medications, potentially ...

Brokerage firm Nuvama has highlighted concerns about BPCL's weak refining margin environment and LPG under-recoveries, which are impacting its earnings. Additionally, the high capital expenditure ...

This is the first time Indus Towers has received a ₹575 target, making it the highest among analysts covering the telecom ...

This steady growth in HDFC Bank's core earnings - both NII and net profit - came in despite a marginal rise in NPAs and NPA ...

Shares of Zomato surged as much as 7.27% to reach INR 261.75 during the intraday trading session on the BSE today (January 16 ...

The brokerage firm has also added Zomato to its high conviction outperform list, saying the recent correction is a buying ...

CLSA has initiated coverage on Hyundai Motor India with an 'Outperform' rating and a target price of Rs 2,155, citing strong ...

The brokerage raised its price target on Dalmia to ₹2,110, implying an upside of 17% and on ACC to ₹2,580, implying gains of 28.5% over Wednesday's closing price.